Two new transition metal complexes of a dipyrazinylpyridine (dppy) ligand 3,4-diethoxyphenyl-2,6-di(pyrazine-2-yl)pyridine L, have been synthesized and characterised using NMR (for L and 2), UV-Vis spectroscopy, ESR (for 1), HRMS, elemental analysis and DFT study. Upon interaction with Bovine Serum Albumin (BSA), complexes 1 and 2 demonstrated varying binding capabilities, with 1 displaying superior binding (binding constant 4.5 x104 M-1), towards BSA than 2 (binding constant 1.2 x104 M-1). Similarly, with calf-thymus DNA (ct-DNA), 1 showed better binding affinity (1.1 x106 M-1) than 2 (8.5 x105 M-1) as observed from UV-Visible spectroscopy. The mechanism that leads to the quenching of BSA fluorescence by 1 and 2 is attributed to static quenching. The complexes demonstrated an intercalative binding mode with ct-DNA, and molecular docking has been employed to elucidate the biomolecular interactions with the complexes. Circular dichroism spectra have been utilised to confirm the binding and assessment of the interactions with the biomolecules. Further, studies of the anticancer potentials of 1-2 were evaluated using the Dalton's lymphoma (DL) cancer cell line. Following 48 hours of treatment, the IC50 for 1 and 2 were identified as 24 μM and 28 μM, respectively, indicating their potency in inhibiting cancer cell growth.